Rhythm Pharmaceuticals Up: Thursday Is PDUFA Goal Date

 Shares of Rhythm Pharmaceuticals Inc., which focuses on drugs for rare genetic diseases of obesity, were recently up 12%, to $3.85.

Thursday is the Prescription Drug User Fee Act goal date for the company's supplemental New Drug Application for Imcivree, for patients with Bardet-Biedl Syndrome or Alström syndrome. The U.S. Food and Drug Administration approved the drug in November 2020 for chronic weight management for patients with three rare genetic conditions.

https://www.marketscreener.com/quote/stock/RHYTHM-PHARMACEUTICALS-I-37977152/news/Rhythm-Pharmaceuticals-Up-12-Thursday-Is-PDUFA-Goal-Date-40744935/